These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10933652)

  • 21. In vivo selection of OmpK35-deficient mutant after cefuroxime therapy for primary liver abscess caused by Klebsiella pneumoniae.
    Lee CH; Chia JH; Chu C; Wu TL; Liu JW; Su LH
    J Antimicrob Chemother; 2006 Oct; 58(4):857-60. PubMed ID: 16880175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative activity of ertapenem against extended-spectrum beta-lactamase-producing or plasmid-mediated AmpC beta-lactamase-producing Klebsiella pneumoniae].
    Hernández JR; Conejo Mdel C; Pascual A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):27-30. PubMed ID: 19631421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia.
    Palasubramaniam S; Muniandy S; Navaratnam P
    J Microbiol Immunol Infect; 2009 Apr; 42(2):129-33. PubMed ID: 19597644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins.
    Martínez-Martínez L; Hernández-Allés S; Albertí S; Tomás JM; Benedi VJ; Jacoby GA
    Antimicrob Agents Chemother; 1996 Feb; 40(2):342-8. PubMed ID: 8834877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Park YJ; Yu JK; Park KG; Park YG; Lee S; Kim SY; Jeong SH
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):87-9. PubMed ID: 21397426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
    Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The mechanism of high-level carbapenem resistance in Klebsiella pneumoniae: underlying Ompk36-deficient strains represent a threat of emerging high-level carbapenem-resistant K. pneumoniae with IMP-1 β-lactamase production in Japan.
    Sho T; Muratani T; Hamasuna R; Yakushiji H; Fujimoto N; Matsumoto T
    Microb Drug Resist; 2013 Aug; 19(4):274-81. PubMed ID: 23514607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Osmotic Stress Increases OmpK36 Expression through the Regulation of KbvR to Decrease the Antimicrobial Resistance of Klebsiella pneumoniae.
    Wang M; Tian Y; Xu L; Zhang F; Lu H; Li M; Li B
    Microbiol Spectr; 2022 Jun; 10(3):e0050722. PubMed ID: 35658577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
    Padilla E; Alonso D; Doménech-Sánchez A; Gomez C; Pérez JL; Albertí S; Borrell N
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2258-60. PubMed ID: 16723600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
    Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-spectrum beta-lactamases and the permeability barrier.
    Martínez-Martínez L
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():82-9. PubMed ID: 18154531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
    Tängdén T; Adler M; Cars O; Sandegren L; Löwdin E
    J Antimicrob Chemother; 2013 Jun; 68(6):1319-26. PubMed ID: 23478794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam.
    Pagès JM; Peslier S; Keating TA; Lavigne JP; Nichols WW
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1349-59. PubMed ID: 26666933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of cefepime and other beta-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae.
    Chen HY; Livermore DM
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():63-74. PubMed ID: 8150768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss.
    Lee K; Yong D; Choi YS; Yum JH; Kim JM; Woodford N; Livermore DM; Chong Y
    Int J Antimicrob Agents; 2007 Feb; 29(2):201-6. PubMed ID: 17204406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem.
    Pragai Z; Nagy E
    J Antimicrob Chemother; 1998 Dec; 42(6):821-4. PubMed ID: 10052909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Porin loss in Klebsiella pneumoniae clinical isolates impacts production of virulence factors and survival within macrophages.
    Brunson DN; Maldosevic E; Velez A; Figgins E; Ellis TN
    Int J Med Microbiol; 2019; 309(3-4):213-224. PubMed ID: 31010630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.
    Nelson K; Hemarajata P; Sun D; Rubio-Aparicio D; Tsivkovski R; Yang S; Sebra R; Kasarskis A; Nguyen H; Hanson BM; Leopold S; Weinstock G; Lomovskaya O; Humphries RM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.
    Humphries RM; Hemarajata P
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396547
    [No Abstract]   [Full Text] [Related]  

  • 40. Membrane permeability modifications are involved in antibiotic resistance in Klebsiella pneumoniae.
    Chevalier J; Pagès JM; Eyraud A; Malléa M
    Biochem Biophys Res Commun; 2000 Aug; 274(2):496-9. PubMed ID: 10913366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.